Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer

dc.contributor.authorKays, Joshua K.
dc.contributor.authorShahda, Safi
dc.contributor.authorStanley, Melissa
dc.contributor.authorBell, Teresa M.
dc.contributor.authorO'Neill, Bert H.
dc.contributor.authorKohli, Marc D.
dc.contributor.authorCouch, Marion E.
dc.contributor.authorKoniaris, Leonidas G.
dc.contributor.authorZimmers, Teresa A.
dc.contributor.departmentSurgery, School of Medicineen_US
dc.date.accessioned2019-05-06T19:24:58Z
dc.date.available2019-05-06T19:24:58Z
dc.date.issued2018-08
dc.description.abstractBACKGROUND: By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy. METHODS: We performed a retrospective review of 53 patients with advanced PDAC on 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin as first line therapy at Indiana University Hospital from July 2010 to August 2015. Demographic, clinical, and survival data were collected. Body composition measurement by computed tomography (CT), trend, univariate, and multivariate analysis were performed. RESULTS: Among all patients, three cachexia phenotypes were identified. The majority of patients, 64%, had Muscle and Fat Wasting (MFW), while 17% had Fat-Only Wasting (FW) and 19% had No Wasting (NW). NW had significantly improved overall median survival (OMS) of 22.6 months vs. 13.0 months for FW and 12.2 months for MFW (P = 0.02). FW (HR = 5.2; 95% confidence interval = 1.5-17.3) and MFW (HR = 1.8; 95% confidence interval = 1.1-2.9) were associated with an increased risk of mortality compared with NW. OMS and risk of mortality did not differ between FW and MFW. Progression of disease, sarcopenic obesity at diagnosis, and primary tail tumours were also associated with decreased OMS. On multivariate analysis, cachexia phenotype and chemotherapy response were independently associated with survival. Notably, CT-based body composition analysis detected tissue loss of >5% in 81% of patients, while the traditional definition of >5% body weight loss identified 56.6%. CONCLUSIONS: Distinct cachexia phenotypes were observed in this homogeneous population of patients with equivalent stage, diagnosis, and first-line treatment. This suggests cellular, molecular, or genetic heterogeneity of host or tumour. Survival among patients with FW was as poor as for MFW, indicating adipose tissue plays a crucial role in cachexia and PDAC mortality. Adipose tissue should be studied for its mechanistic contributions to cachexia.en_US
dc.identifier.citationKays, J. K., Shahda, S., Stanley, M., Bell, T. M., O'Neill, B. H., Kohli, M. D., … Zimmers, T. A. (2018). Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. Journal of cachexia, sarcopenia and muscle, 9(4), 673–684. doi:10.1002/jcsm.12307en_US
dc.identifier.urihttps://hdl.handle.net/1805/19139
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/jcsm.12307en_US
dc.relation.journalJournal of Cachexia, Sarcopenia and Muscleen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.sourcePMCen_US
dc.subjectCachexiaen_US
dc.subjectFOLFIRINOXen_US
dc.subjectMuscle wastingen_US
dc.subjectPancreatic canceren_US
dc.subjectSarcopeniaen_US
dc.titleThree cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic canceren_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
JCSM-9-673.pdf
Size:
638.76 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: